The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.
 
Richard Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Medivir; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; EISAI; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Tim Meyer
Consulting or Advisory Role - AstraZeneca; Bayer; Grey Wolf Therapeutics; Guerbet; Roche; Signant Health
Research Funding - MSD (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Guardant Health; Incyte; Lilly Japan; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Ruocai Xu
No Relationships to Disclose
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Guerbet; Incyte; Ipsen; Jazz Pharmaceuticals; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology
Research Funding - AstraZeneca (Inst); Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Exeliom Biosciences; Summit Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Zhenggang Ren
Consulting or Advisory Role - MSD; Roche
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; IPSEN; MSD Oncology; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Peter Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - AstraZeneca; Bayer Schering Pharma; BMS GmbH & Co. KG; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bayer Schering Pharma; Lilly; Roche/Genentech; Sirtex Medical
 
Shuichi Kaneko
No Relationships to Disclose
 
Hiromitsu Kumada
Honoraria - Sumitomo-pharma, Eisai, AbbVie, Gilead Sciences
Speakers' Bureau - Sumitomo-pharma, Eisai, AbbVie, Gilead Sciences
 
Simcha Pollack
Employment - Merck
 
Kalgi Mody
Employment - Eisai; Eisai
Travel, Accommodations, Expenses - Eisai; Eisai
 
Leonid Dubrovsky
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
David Adelberg
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Josep Llovet
Consulting or Advisory Role - Abbvie; Astrazeneca; Bayer; Eisai; Exelixis; Genentech; Glycotest; Merck; Moderna Therapeutics; Roche; Sanofi
Research Funding - Bayer (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - Bayer